Frunevetmab

Modify Date: 2024-01-06 17:23:01

Frunevetmab structure	Common Name	Frunevetmab
	CAS Number	1708936-80-4	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Frunevetmab

Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats[1][2].

Name	Frunevetmab

Description	Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
Target	Kd: 20 pM (NGF)[2]
In Vitro	Frunevetmab (NV-02) neutralizes NGF with high affinity and potency and does not bind complement[2].
In Vivo	Frunevetmab (1.0-2.8 mg/kg; s.c; on days 0, 28, and 56) shows positive treatment effects in cats with naturally-occurring OA pain and associated mobility impairment and disability[1]. Animal Model: Cats with naturally-occurring OA pain and associated mobility impairment and disability[1] Dosage: 1.0-2.8 mg/kg Administration: s.c; 3 times at 28-day intervals; on days 0, 28, and 56 Result: Reliefed the pain from osteoarthritis in cats.
References	[1]. Margaret E Gruen, et al. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med. 2021 Nov;35(6):2752-2762. [2]. D P Gearing, et al. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats. J Vet Intern Med. 2016 Jul;30(4):1129-37.

No Any Chemical & Physical Properties

Frunevetmab

Use of Frunevetmab

Names

Frunevetmab Biological Activity

Chemical & Physical Properties